Prothena (STU:0PT) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 27, 2026)


STU:0PT Prothena Corp PLC STU:0PT
78 GF Score
Price €8.72
GF Value €12.85
! 3 Warning Signs
View Full Analysis

What is Prothena Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Prothena's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

STU:0PT vs EDIT, ACHV, XOMA: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, Prothena's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prothena Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prothena's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Prothena's Margin of Safety % (DCF FCF Based) falls into.


STU:0PT
78GF Score
Prothena Corp PLC STU:0PT
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Prothena (STU:0PT) Overvalued in 2026?

Based on GuruFocus' analysis, Prothena stock appears to be undervalued. The current stock price of €8.72 is trading 32.2% below its estimated GF Value™ of €12.85.

Key valuation signals for STU:0PT:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: €12.85 vs. price of €8.72 (32.2% below fair value)
  • GF Score™: 78/100 with 3 warning signs

No single metric tells the full story. See the STU:0PT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Prothena Business Description

Other Exchanges PRTA:USA0Y3M:UK0PT:Germany
Address 77 Sir John Rogerson’s Quay, Block C, Grand Canal Docklands, Dublin 2, Dublin, IRL, D02 VK60
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
78GF Score

Get the complete analysis for STU:0PT

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.72
Price
€12.85
GF Value